Chapter 389: Mechanisms of Hormone Action¶
Chapter 389 | Part 12: Endocrinology and Metabolism
KEY CLINICAL POINTS¶
- Hormones are classified into five major types: amino acid derivatives, neuropeptides, large proteins, steroid hormones, and vitamin derivatives.
- Hormone-receptor interactions are mediated by membrane receptors (peptide hormones, catecholamines) and nuclear receptors (steroids, thyroid hormones, vitamin D).
- Feedback regulation (negative/positive) is critical for maintaining hormonal homeostasis across endocrine axes (e.g., HPA, HPT, HPG).
- Dynamic testing (e.g., dexamethasone suppression, ACTH stimulation) is essential for diagnosing endocrine disorders when biochemical tests are inconclusive.
- Nuclear receptors (e.g., thyroid hormone receptor β ) can exhibit dominant-negative mutations, leading to resistance to thyroid hormone (RTH).
1. DEFINITION & OVERVIEW¶
The endocrine system regulates growth, metabolism, homeostasis, and reproduction via hormones. Hormones act through membrane receptors (peptides, catecholamines) or nuclear receptors (steroids, thyroid hormones, vitamin D). Hormone action involves complex signaling pathways, including G protein-coupled receptors (GPCRs), tyrosine kinase receptors, and nuclear receptor-mediated transcription.
Table 389-1: Membrane Receptor Families and Signaling Pathways¶
| RECEPTORS | EFFECTORS | SIGNALING PATHWAYS |
|---|---|---|
| G Protein–Coupled Seven-Transmembrane Receptor (GPCR) | LH, FSH, TSH, b-adrenergic, Glucagon, PTH, ACTH, MSH, GHRH, CRH, Somatostatin, a-adrenergic, TRH, GnRH | Stimulation of cyclic AMP, Inhibition of cyclic AMP, Phospholipase C, JAK/STAT, Serine kinase |
| Receptor Tyrosine Kinase | Insulin, IGF-I, GH, PRL | Tyrosine kinases, JAK, STAT, MAP kinase, PI 3-kinase |
| Cytokine Receptor–Linked Kinase | GH, PRL | JAK, tyrosine kinases, STAT, MAP kinase, PI 3-kinase, IRS-1 |
| Serine Kinase | Activin, TGF-b, MIS | Serine kinase, Smads |
1.1 Hormone Classes¶
Five major classes: (1) amino acid derivatives (e.g., dopamine, catecholamines, thyroid hormone); (2) neuropeptides (e.g., GnRH, TRH); (3) large proteins (e.g., insulin, PTH); (4) steroid hormones (e.g., cortisol, estrogen); (5) vitamin derivatives (e.g., retinoids, vitamin D).
1.2 Receptor Types¶
Membrane receptors (GPCRs, tyrosine kinase, cytokine receptors) and nuclear receptors (steroid, thyroid, vitamin D). Nuclear receptors bind hydrophobic ligands and regulate gene transcription.
2. ETIOLOGY & PATHOPHYSIOLOGY¶
Hormone synthesis and action involve complex pathways. Peptide hormones (e.g., ACTH, insulin) are derived from precursor polypeptides, while steroid hormones (e.g., cortisol) are synthesized from cholesterol. Hormone secretion is regulated by feedback loops, with dynamic tests (e.g., suppression, stimulation) used to assess endocrine function.
Table 389-2: Genetic Causes of G Protein Receptor Disorders¶
| RECEPTOR | DISORDER | GENETICS |
|---|---|---|
| LH | Leydig cell hypoplasia (male) | AR, inactivating |
| LH | Primary amenorrhea, resistance to LH (female) | AR, inactivating |
| LH | Familial male precocious puberty (male) | AD, activating |
| LH | Leydig cell adenoma, precocious puberty (male) | Sporadic, activating |
| FSH | Hypergonadotropic ovarian failure (female) | AR, inactivating |
| FSH | Hypospermia (male) | Sporadic, activating |
| FSH | Ovarian hyperstimulation (female) | |
| TSH | Congenital hypothyroidism, TSH resistance | AR, AD, inactivating |
| TSH | Nonautoimmune familial hyperthyroidism | AD, activating |
| TSH | Hyperfunctioning thyroid adenoma | Sporadic, activating |
| GnRH | Hypogonadotropic hypogonadism | AR, inactivating |
| Kisspeptin | Hypogonadotropic hypogonadism | AR, inactivating |
| Kisspeptin | Precocious puberty | AD, activating |
| TRH | Central hypothyroidism | AR, inactivating |
| GHRH | GH deficiency | AR, inactivating |
| PTH | Blomstrand chondrodysplasia | AR, inactivating |
| PTH | Jansen metaphyseal chondrodysplasia | AD, activating |
| Calcium sensing receptor | Familial hypocalciuric hypercalcemia | AD, inactivating |
| Calcium sensing receptor | Neonatal severe hyperparathyroidism | AR, inactivating |
| Calcium sensing receptor | Familial hypocalcemic hypercalciuria | AD, activating |
| Arginine vasopressin receptor 2 | Nephrogenic diabetes insipidus | XL, inactivating |
| Arginine vasopressin receptor 2 | Nephrogenic SIADH | XL, activating |
| RECEPTOR | DISORDER | GENETICS |
|---|---|---|
| ACTH | Familial ACTH resistance | AR, inactivating |
| ACTH | ACTH-independent Cushing syndrome | Sporadic, activating |
| Melanocortin 4 receptor | Severe obesity | Codominant, inactivating |
2.1 Hormone Synthesis¶
Peptide hormones (e.g., POMC → ACTH, proinsulin → insulin) are processed via proteolytic cleavage. Steroid hormones (e.g., testosterone, cortisol) are synthesized from cholesterol via enzymatic steps. Nuclear receptors (e.g., TR, GR) regulate gene transcription in response to ligand binding.
2.2 Hormone Action Mechanisms¶
Membrane receptors (GPCRs, tyrosine kinase) activate intracellular signaling (e.g., cAMP, MAPK). Nuclear receptors (e.g., TR, GR) bind DNA to modulate gene expression. Cross-talk between membrane and nuclear receptors (e.g., estrogen receptor interactions with environmental estrogens) influences physiological responses.
3. CLINICAL FEATURES¶
Hormone imbalances affect growth, homeostasis, and reproduction. For example, GH deficiency causes short stature, while hyperthyroidism (e.g., Graves’ disease) leads to weight loss and tachycardia. Hormone feedback loops (e.g., HPA axis) regulate endocrine function and maintain physiological stability.
3.1 Growth Regulation¶
GH and IGF1 drive growth, with epiphyseal closure mediated by sex steroids. Disorders like Turner syndrome (45,X) or FGFR3 mutations cause short stature. Precocious puberty (e.g., due to GnRH analogs) accelerates growth plate closure.
3.2 Homeostasis¶
Thyroid hormone (T4) and cortisol regulate metabolism, while PTH and vitamin D maintain calcium homeostasis. Insulin manages glucose homeostasis, and vasopressin regulates water balance.
4. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic tests include immunoassays (e.g., TSH, cortisol), dynamic tests (e.g., dexamethasone suppression, ACTH stimulation), and imaging (e.g., ultrasound, MRI). Hormone half-life and binding proteins (e.g., TBG, SHBG) influence interpretation of serum levels.
Table 389-1: Membrane Receptor Families and Signaling Pathways¶
| RECEPTORS | EFFECTORS | SIGNALING PATHWAYS |
|---|---|---|
| G Protein–Coupled Seven-Transmembrane Receptor (GPCR) | LH, FSH, TSH, b-adrenergic, Glucagon, PTH, ACTH, MSH, GHRH, CRH, Somatostatin, a-adrenergic, TRH, GnRH | Stimulation of cyclic AMP, Inhibition of cyclic AMP, Phospholipase C, JAK/STAT, Serine kinase |
| Receptor Tyrosine Kinase | Insulin, IGF-I, GH, PRL | Tyrosine kinases, JAK, STAT, MAP kinase, PI 3-kinase |
| Cytokine Receptor–Linked Kinase | GH, PRL | JAK, tyrosine kinases, STAT, MAP kinase, PI 3-kinase, IRS-1 |
| RECEPTORS | EFFECTORS | SIGNALING PATHWAYS |
|---|---|---|
| Serine Kinase | Activin, TGF-b, MIS | Serine kinase, Smads |
4.1 Hormone Measurement¶
Immunoassays detect picomolar to nanomolar concentrations. Urinary tests (e.g., 24-h free cortisol, 17-hydroxycorticosteroids) assess endocrine function. Binding proteins (e.g., TBG, SHBG) modulate free hormone availability.
4.2 Dynamic Testing¶
Suppression tests (e.g., dexamethasone for Cushing’s) and stimulation tests (e.g., ACTH for adrenal insufficiency) evaluate endocrine reserve. Feedback loops (e.g., TRH-TSH) guide interpretation.
5. MANAGEMENT & TREATMENT¶
Treatment depends on hormone type and disorder. Hormone replacement (e.g., thyroid hormone, glucocorticoids) and receptor modulators (e.g., SERMs, antagonists) are used. Surgical intervention (e.g., parathyroidectomy) may be required for tumors or hyperplasia.
5.1 Pharmacologic Therapy¶
Hormone replacement (e.g., T4 for hypothyroidism, GH for growth failure). Antagonists (e.g., octreotide for somatostatin analogs) and modulators (e.g., tamoxifen for estrogen receptor) target specific pathways.
5.2 Non-Pharmacologic Approaches¶
Lifestyle modifications (e.g., diet, exercise) for metabolic disorders. Surgical removal of tumors (e.g., adrenal adenomas) or parathyroidectomy for hyperparathyroidism.
6. PROGNOSIS & COMPLICATIONS¶
Prognosis varies by disorder. Hormone resistance (e.g., RTH) or tumors (e.g., ACTH-secreting adenomas) may lead to chronic complications. Early diagnosis and treatment improve outcomes, particularly in congenital disorders (e.g., congenital hypothyroidism).
6.1 Complications¶
Hormone resistance (e.g., TR β mutations), tumor growth (e.g., autonomous hyperfunctioning nodules), and metabolic disturbances (e.g., hypercalcemia, hypoglycemia).
6.2 Long-Term Outcomes¶
Early intervention (e.g., neonatal thyroid hormone replacement) prevents developmental delays. Chronic conditions (e.g., Cushing’s syndrome) require lifelong management.
7. SPECIAL CONSIDERATIONS¶
Special populations (e.g., pregnancy, elderly) require tailored approaches. Hormone binding proteins (e.g., TBG, SHBG) and physiological variations (e.g., circadian rhythms) affect interpretation of tests. Genetic counseling is critical for inherited disorders (e.g., MEN, RTH).
7.1 Pregnancy¶
Hormonal adaptations (e.g., increased PRL, estrogen) support fetal development. Maternal thyroid function (e.g., TSH) must be monitored to prevent fetal complications.
7.2 Pediatric Considerations¶
Growth hormone deficiency and precocious puberty require early diagnosis. Hormone-binding proteins (e.g., TBG) vary with age and sex.
8. KEY POINTS & CLINICAL PEARLS¶
- Hormones are classified into five major types with distinct mechanisms of action. 2. Hormone-receptor interactions involve membrane (GPCRs, tyrosine kinase) and nuclear (steroid, thyroid) pathways. 3. Feedback regulation (e.g., HPA, HPT) maintains hormonal homeostasis. 4. Dynamic testing (e.g., suppression, stimulation) is essential for diagnosing endocrine disorders. 5. Genetic mutations (e.g., TR β , GPCR) can cause hormone resistance or hyperfunction.